STOCK TITAN

Healthcare AI Acq CP A (HAIAF) Stock Price, News & Analysis

HAIAF OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
1 41 sessions, November 14, 2024 to November 14, 2025
Largest daily move
-6.3% close of December 16, 2024

Company Description

Healthcare AI Acquisition Corp. (traded under the symbol HAIAF) is a Cayman Islands exempted company that has been formed to pursue an initial business combination. According to its SEC filings, the company is organized as Healthcare AI Acquisition Corp. and has ordinary shares and warrants outstanding. Its securities have been quoted on the OTC Markets Group Pink Open Market, and it files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-41145.

The company describes itself in regulatory documents as seeking to complete an initial business combination, sometimes referred to as a business combination or proposed business combination. Healthcare AI Acquisition Corp. maintains a trust account in which proceeds from its initial public offering were deposited. Public shareholders hold Class A ordinary shares, while there is also a Class B ordinary share structure referenced in its proxy materials. Shareholders have the right, in connection with certain shareholder meetings, to redeem their public shares for a pro rata portion of the funds held in the trust account.

Corporate structure and jurisdiction

Healthcare AI Acquisition Corp. is incorporated in the Cayman Islands, as disclosed in multiple Form 8-K and proxy filings. Its SEC filings list a Cayman Islands company number and U.S. tax identification number, reflecting its status as a foreign private issuer for corporate law purposes while being subject to U.S. securities regulation for its registered securities.

Business combination timeline and extensions

The company’s Articles of Association set a deadline by which it must consummate a business combination. In its definitive proxy statement and subsequent Form 8-K filings, Healthcare AI Acquisition Corp. describes shareholder votes on proposals to extend this deadline. The company has sought and obtained the right, via special resolutions of shareholders, to extend the date by which it must complete a business combination on a month-to-month basis by depositing a fixed amount per non-redeemed public share into the trust account for each extension.

These extensions are referred to in filings as the Extension Proposal or Extension Amendment Proposal. The board of directors may approve additional extensions up to an extended termination date, subject to the terms approved by shareholders. If the company does not complete a business combination by the applicable termination date and does not obtain further extensions, its filings state that it would cease all operations except for the purpose of winding up and would redeem 100% of the outstanding public shares from the trust account.

Trust account and shareholder redemptions

Healthcare AI Acquisition Corp. provides detailed information in its proxy statements and Form 8-K filings about the trust account and redemption mechanics. Holders of Class A ordinary shares issued in the IPO, referred to as public shares, may elect to redeem their shares in connection with certain shareholder meetings. The redemption price per public share is calculated as the pro rata amount in the trust account, including interest not previously used to pay taxes, divided by the number of outstanding public shares.

The company’s filings describe prior redemption events where a substantial number of public shares were redeemed, and corresponding amounts were removed from the trust account to pay redeeming shareholders. Following such redemptions, the filings specify the number of remaining Class A shares and the amount remaining in the trust account. The documents also note that the market price of the public shares on the OTC Pink Open Market may differ from the redemption price and that trading liquidity may be limited.

Healthcare AI Acquisition Corp. has a sponsor entity, identified in its proxy statement as Atticus Ale LLC, which assumed sponsorship from an initial sponsor through a share transfer referred to as the Sponsor Handover. The filings describe founder shares (Class B ordinary shares) held by the sponsor and other initial shareholders, and the ability to convert these founder shares into Class A ordinary shares on a one-for-one basis prior to the closing of a business combination.

The company’s disclosures also describe agreements regarding private placement warrants purchased at the time of the IPO and arrangements under which a portion of those warrants may be surrendered for cancellation in exchange for Class A ordinary shares at the time of the initial business combination. These features are part of the capital structure that supports the company’s efforts to complete a business combination.

Proposed business combination

In its filings, Healthcare AI Acquisition Corp. states that it has identified a potential business combination target, referred to as the Target, and a proposed business combination. The company has entered into a business combination agreement with entities identified as Leading Partners Limited and Leading Group Limited, both Cayman Islands companies, for purposes of completing a business combination. The proxy statement and subsequent Form 8-K filings describe changes to the outside date by which this proposed business combination must be completed and the related extension mechanics.

Shareholders are informed that they are not being asked to vote on the business combination itself in the extension-related proxy materials. Instead, the purpose of the extension proposals is to provide additional time for Healthcare AI Acquisition Corp. to seek to consummate the proposed business combination.

Regulatory reporting and late filing notice

Healthcare AI Acquisition Corp. files periodic reports with the SEC and, when necessary, submits notifications of late filing. In a Form 12b-25 (NT 10-Q), the company reported that it was unable to file its Quarterly Report on Form 10-Q for a specified fiscal quarter by the prescribed due date due to difficulty in completing and obtaining required financial and other information without unreasonable effort and expense. In that notification, the company indicated that it expected to file the report within the extension period allowed under SEC rules and stated that it did not anticipate a significant change in results of operations compared to the corresponding period of the prior year.

Shareholder meetings and governance

The company’s definitive proxy statement invites shareholders to an annual general meeting and outlines the matters to be voted upon, including the extension proposal, ratification of the independent registered public accounting firm, and a potential adjournment proposal. The filings describe the voting thresholds required under Cayman Islands law for special and ordinary resolutions, and they provide the results of shareholder votes in subsequent Form 8-K filings.

Healthcare AI Acquisition Corp. emphasizes in its proxy materials that if the extension proposal and related contributions to the trust account are not approved, and if a business combination is not completed by the existing termination date, the company would be required to dissolve and redeem the public shares in accordance with its Articles of Association.

Trading venue and investor considerations

The company’s proxy statement notes that its public shares trade on the OTC Markets Group Pink Open Market. It also cautions that there may not be sufficient liquidity in its securities at any given time and that shareholders may not be able to sell their public shares in the open market, even if the market price is lower than the redemption price available in connection with certain shareholder votes.

Overall, Healthcare AI Acquisition Corp. functions as a special purpose entity focused on completing an initial business combination within a defined timeframe, subject to shareholder approvals and extensions. Its SEC filings provide detailed information on its capital structure, trust account, redemption rights, sponsor arrangements, and the procedural steps required to complete or, if necessary, wind up its operations.

Stock Performance

$12.74
No recent trading
Last close: November 14, 2025
-
1 year to November 14, 2025

Healthcare AI Acq CP A (HAIAF) closed at $12.74 on November 14, 2025.

See what a $1,000 investment in HAIAF would be worth today

Average down calculator for HAIAF

HAIAF Metrics & Rankings

Price returns through November 14, 2025. Ranking links may use different dates.

Latest News

No recent news available for HAIAF.

Financial Highlights

Healthcare AI Acq CP A reported operating income of -$671K in FY2024, and net income was $57K. The company generated -$446K in operating cash flow. The current ratio was 0.44, measuring current assets divided by current liabilities.

$57K
Net Income (FY2024)
-$446K
Operating Cash Flow
—
Revenue (FY2024)

Upcoming Events

No upcoming events scheduled for HAIAF.

Short Interest History

Last 12 Months

Short interest in Healthcare AI Acq CP A (HAIAF) currently stands at 17.3 thousand shares, up 2839.8% from the previous reporting period, representing 7.5% of the float. Since November 2025, short interest has increased by 2839.8%.

Days to Cover History

Last 12 Months

Days to cover for Healthcare AI Acq CP A (HAIAF) currently stands at 1000.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 99899%. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.

HAIAF Company Profile & Sector Positioning

Healthcare AI Acq CP A (HAIAF) operates in the Shell Companies industry within the broader Financial Services sector and is listed on the OTC.

Investors comparing HAIAF often look at related companies in the same sector, including Chain Bridge I A (CBRRF), Intl Media Acq Corp A (IMAQ), Quetta Acquisition Corp (QETA), Piermont Valley Acq A (CMCAF), and Metalink Ltd (MTLK). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate HAIAF's relative position within its industry.

Frequently Asked Questions

Healthcare AI Acq CP A (HAIAF) has no recent trading. Its last close was $12.74 on November 14, 2025.

The FY2024 net income of Healthcare AI Acq CP A (HAIAF) is $57K, from its most recent completed fiscal year.

The operating cash flow of Healthcare AI Acq CP A (HAIAF) is -$446K for FY2024, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Healthcare AI Acq CP A (HAIAF), current assets divided by current liabilities, was 0.44 at the end of FY2024, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Healthcare AI Acq CP A (HAIAF) is -$671K for FY2024, its most recent completed fiscal year. Learn about operating income.

Healthcare AI Acquisition Corp. is a Cayman Islands exempted company that has raised capital to complete an initial business combination. Its structure includes public Class A ordinary shares, a Class B ordinary share, and warrants, with proceeds from its offering held in a trust account for the benefit of shareholders.

According to its SEC filings, Healthcare AI Acquisition Corp. maintains a trust account in which funds from its initial public offering are held. When shareholders approve extensions of the deadline to complete a business combination, specified amounts are deposited into the trust account per non-redeemed public share. Public shareholders may redeem their shares for a pro rata portion of the funds in the trust account in connection with certain shareholder meetings.

The extension proposals, described in the company’s proxy statements and Form 8-K filings, seek shareholder approval to extend the date by which Healthcare AI Acquisition Corp. must complete a business combination. If approved, the board may extend this date on a month-to-month basis by arranging for contributions to the trust account, allowing more time to pursue a proposed business combination.

The company’s proxy materials state that if a business combination is not completed by the applicable termination date and no further extensions are obtained, Healthcare AI Acquisition Corp. will cease all operations except for the purpose of winding up. It would then redeem 100% of the outstanding public shares for a pro rata portion of the funds in the trust account in accordance with its Articles of Association.

Filings identify Atticus Ale LLC as the sponsor of Healthcare AI Acquisition Corp., following a transfer of founder shares from an initial sponsor. The sponsor has agreed, if the extension proposal is approved, to contribute a fixed amount per non-redeemed Class A ordinary share per month to the trust account as loans to the company for each extension, repayable upon consummation of an initial business combination and subject to the terms described in the proxy statement.

Healthcare AI Acquisition Corp. discloses that it has identified a potential business combination target and refers to a proposed business combination. It has entered into a business combination agreement with Leading Partners Limited and Leading Group Limited, Cayman Islands companies, for purposes of completing this transaction. The extension proposals are intended to provide additional time to pursue this proposed business combination.

The company’s definitive proxy statement notes that its public shares are quoted on the OTC Markets Group Pink Open Market. The filings also caution that trading liquidity may be limited and that shareholders may not always be able to sell shares in the open market at prices comparable to the redemption price available in connection with certain shareholder votes.

Healthcare AI Acquisition Corp. filed a Form 12b-25 to notify the SEC that it could not file its Quarterly Report on Form 10-Q for a specified quarter by the prescribed due date. The filing states that the company had difficulty completing and obtaining required financial and other information without unreasonable effort and expense, and that it expected to file the report within the extension period allowed under SEC rules.

The company’s proxy statement explains that under Cayman Islands law, certain proposals, such as amendments to the Articles of Association to extend the business combination deadline, require approval as a special resolution, which involves a specified supermajority of votes cast. Other matters, such as ratification of the independent registered public accounting firm, require approval as ordinary resolutions by a majority of votes cast.

Healthcare AI Acquisition Corp.’s filings describe founder shares as Class B ordinary shares held by the sponsor and other initial shareholders, which may be converted into Class A ordinary shares on a one-for-one basis prior to the closing of a business combination. The company also issued private placement warrants at the time of its IPO and has agreements under which a large number of these warrants may be surrendered for cancellation in exchange for a specified number of Class A ordinary shares at the time of the initial business combination.